adults

REED AUTISM SERVICES AND NEWHD MEDIA FORGE INNOVATIVE PARTNERSHIP TO EMPOWER INDIVIDUALS WITH AUTISM IN BROADCASTING

[gallery columns="2" size="medium" link="none" ids="2892134,2892135"] [Franklin Lakes, NJ] – REED Autism Services, a leading non-profit organization providing programs and services to individuals with autism throughout their lifetime, has joined forces with NEWHD Media, a unique media platform that provides jobs for people with autism spectrum disorder (ASD), to create transformative opportunities in the field of broadcasting. Studies show that nearly half of all 25-year-olds with autism have never held a paying job. REED and NEWHD Media are working together to break down barriers and offer avenues for personal and professional

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating